Lilly reshuffles business unit execs
Alex M. Azar II will assume the role of vice president (VP) for Ely Lilly's U.S. business-to-business organization, and Jack Bailey will broaden his responsibilities as U.S. senior VP of account-based markets to include oversight of Lilly's U.S. diabetes business unit, effective April 1.

Azar, who previously was senior VP of corporate affairs and communications, will now oversee the company's public payor, managed care and wholesaler operations in the U.S. as well as oversee Lilly's sales and marketing operations in Puerto Rico.

Baily will add to his current responsibilities for Lilly's U.S. oncology and cardiovascular teams, as well as the Lilly Hospital Group. Bailey's move combines several aspects of the business and creates therapeutic alignment across Lilly's organization, from drug discovery to new product development to commercialization.

Azar joined Lilly in 2007 and, during his tenure Lilly's corporate affairs function, helped position Lilly as an advocate of public policies that support biopharmaceuticals and advocated for healthcare reform. Previously, Azar served as the U.S. Deputy Secretary of Health and Human Services (HHS) from 2005 to 2007, where he worked with Secretary Mike Leavitt and served for almost two years as the chief operating officer.

Bailey joined Lilly in 1991. During his 18-year tenure, he has held positions in sales and marketing and business development. In 1998, he assumed the role of general manager for Lilly's affiliate in South Africa and also directed regional sales operations across Sub-Saharan Africa. In 2001, he returned to the U.S. to lead Lilly's business-to-business organization.